Month: May 2025

PExA files patent to enable RNA fragmentomics in exhaled air— unlocking molecular insights from the small airways

PExA AB, a Swedish life science company pioneering non-invasive lung research, has filed a patent application for a novel method that enables RNA fragmentomics analysis in exhaled air samples—a unique, non-invasive way to access molecular signals from the distal lung. Developed in collaboration with Sweden-based Precision BioAnalytics using RealSeq Biosciences’ proprietary RNA fragmentomics platform, the…

Read more

PExA to showcase non-invasive lung research platform and present at Respiratory Innovation Summit during ATS 2025

PExA AB, a Swedish life science company and pioneer in non-invasive lung research, will participate in the American Thoracic Society (ATS) 2025 International Conference, taking place May 16–21 in San Francisco, California.  Returning for the third consecutive year, PExA will exhibit at ATS — the world’s leading event for pulmonary, critical care, and sleep medicine. At Booth…

Read more

PExA takes the next step — sharpening focus on clinical applications in lung diagnostics

PExA AB, a Swedish life science company and pioneer in non-invasive lung research, today announces a refined strategic direction to translate scientific advances into clinical solutions for early diagnosis and treatment monitoring of lung diseases. In recent years, PExA has focused on advancing its method and leveraging major developments in biochemical analysis. These advances have…

Read more